HDAC9 and neuroblastoma: A recent investigation shows that vorinostat, a well-established histone deacetylase (HDAC) inhibitor, re-programs glycolytic events in neuroblastoma (NB) cells [185], implying that HDACi can influence metabolic events in cancer cells.